Activities

Biotechnology, generic tools and medical technologies for human health High-throughput research: to catalyse progress in fundamental genomics (genome and post-genome) and biomedical research by enhancing data generation, standardisation, acquisition and analysis. Detection, diagnosis and monitoring: with emphasis on non-invasive or minimally invasive approaches and technologies such as new preventive tools for regenerative medicine (e.g. through molecular imaging and diagnostics). Predicting suitability, safety and efficacy of therapies: to develop and validate biological markers, in vivo and in vitro methods and models, including simulation, pharmacogenomics, targeting and delivery approaches and alternatives to animal testing. Innovative therapeutic approaches and intervention: to research, consolidate and ensure further developments in advanced therapies and technologies with potential application in many diseases and disorders such as new therapeutic tools for regenerative medicine. Translating research for human health Integrating biological data and processes — large-scale data gathering, systems biology (including modelling of complex systems): to generate and analyse the vast amount of data needed to understand better the complex regulatory networks of thousands of genes and gene-products controlling important biological processes in all relevant organisms and at all levels of organisation. Research on the brain and related diseases, human development and ageing: to explore the process of healthy ageing and the way genes and environment interact with brain activity both under normal conditions and in brain diseases and relevant age-related illness (e.g. dementia). Translational research in infectious diseases: to address drug resistance, the global threats of HIV/AIDS, malaria and tuberculosis, as well as hepatitis and potentially new and re-emerging epidemics (e.g. SARS and highly pathogenic influenza). Translational research in major diseases — cancer, cardiovascular disease, diabetes/obesity; rare diseases; other chronic diseases including arthritis, rheumatic and musculo-skeletal diseases and respiratory diseases, including those induced by allergies: to develop patient-oriented strategies from prevention to diagnosis with particular emphasis on treatment, including clinical research and the use of active ingredients. Aspects of palliative medicine will be taken into account. Optimising the delivery of health care to European citizens Translating clinical outcome into clinical practice: to create the knowledge bases for clinical decision-making and to address the translation of outcomes of clinical research into clinical practice, especially addressing patient safety and the better use of medicines (including some aspects of pharmacovigilance and scientifically tested complementary and alternative medicines) as well as the specificities of children, women and the elderly population. Quality, efficiency and solidarity of health care systems including transitional health care systems and home-care strategies: to translate effective interventions into management decisions, to assess the cost, efficiency and benefits of different interventions including with regard to patient safety, to define the needs and conditions for an adequate supply of human resources, to analyse factors influencing equity of access to high-quality health care (also by disadvantaged groups), including analyses of changes in population (e.g. ageing, mobility and migration, and the changing workplace). Enhanced disease prevention and better use of medicines: to develop efficient public health interventions addressing wider determinants of health (such as stress, diet, lifestyle or environmental factors and their interaction with medication); to identify successful interventions in different health care settings to improve the prescription of medicines and their use by patients (including pharmacovigilance aspects and interactions of medicines). Appropriate use of new health therapies and technologies: long-term safety and effectiveness assessment and monitoring of large-scale use of new medical technologies (including devices) and advanced therapies to ensure a high level of protection and benefit for public health.

← anx_I__cpt_1__cpt_5__cpt_1__cpt_2__text_8 · All articles · anx_I__cpt_1__cpt_5__cpt_1__cpt_3__text_1 →

Source: EUR-Lex (Cellar) · retrieved 2026-11-04 · Text as adopted (Official Journal); later amendments are not incorporated in this text.